Please assess the completion status of the following clinical trial:

Trial Title: A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Patients had to fulfill all of the following criteria to be eligible for study participation:~* Males or non-pregnant females aged 18 or over.~* Histologically confirmed diagnosis of CTCL, including mycosis fungoides and Sézary syndrome.~* Patients with CTCL stages II-A, II-B, III, and IV-A only.~* Patients with CTCL stage IB who had relapsed following previous therapy and where, in the investigator's opinion, the potential benefit of treatment with romidepsin outweighed the possible risks.~* Patients who had failed standardized skin-directed therapy and had had at least one course of systemic therapy, such as interferon, Ontak®, chemotherapy or Targretin®, etc., which they were deemed to have failed.~* Anticipated life expectancy greater than six months.~* Written informed consent to participate in the study.~Exclusion Criteria: Patients were ineligible for entry if any of the following criteria were met:~* ECOG Performance Status \>1.~* Patients who had not received at least 1 course of prior systemic therapy for CTCL.~* Visceral involvement i.e. Stage 4B disease (lymphadenopathy was allowed).~* Patients with known cardiac abnormalities such as:~  * Congenital long QT syndrome~ * QTc (Corrected QT interval on ECG) interval \>480 milliseconds~ * Any cardiac arrhythmia requiring anti-arrhythmic medication.~* Patients who had had a myocardial infarction within 12 months of study entry.~* Patients who had a history of coronary artery disease (CAD) e.g. angina Canadian class II to IV. In any patient in whom there was doubt, the patient should have had a stress imaging study and exercise electrocardiogram (ECG) and, if abnormal, angiography to define whether or not CAD was present.~* Patients with an ECG recorded at screening showing evidence of cardiac ischaemia (ST depression of \>=2 mm). If in any doubt, the patient should have had a stress imaging study and exercise ECG and, if abnormal, angiography to define whether or not CAD is present.~* Patients with congestive heart failure that met New York Heart Association class II to IV definitions and/or ejection fraction \<40% by multiple gated acquisition (MUGA) scan or \<50% by echocardiogram and/or magnetic resonance imaging (MRI)~* Patients with a history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest, unless currently addressed with an automatic implantable cardioverter defibrillator (AICD).~* Patients with hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above).~* Patients with uncontrolled hypertension, i.e. \>=160/95 mmHg.~* Concomitant use of any anti-cancer therapy.~* Concomitant use of warfarin (due to a drug interaction).~* Concomitant use of any investigational agent.~* Use of any investigational agent within 4 weeks of study entry.~* Concomitant use of drugs which may cause a prolongation of the QTc interval.~* Patients with a potassium level of \<3.5 mmol/L and a magnesium level of \<0.8 mmol/L.~* Clinically significant active infection.~* Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.~* Inadequate bone marrow or other organ function, as evidenced by:~  * unsupported haemoglobin \<9.0 g/dL (transfusions and/or erythropoietin were permitted);~ * absolute neutrophil count (ANC) \<=1.5 x 10\^9/L;~ * platelet count \<100 x 10\^9/L;~ * total bilirubin \>1.25 x upper limit of normal (ULN) for institution,~ * aspartate transaminase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/ glutamic pyruvic transaminase (ALT/SGPT) \>2.0 x ULN, serum creatinine \>2.0 x ULN for age and sex;~* Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin or cervical epithelial neoplasm \[CIN1, carcinoma in situ\] that had been treated curatively).~* Any significant medical or psychiatric condition that might have prevented the patient from complying with all study procedures.~* Patients who were pregnant or breast-feeding. All women of child bearing potential were to use an effective method of contraception (either an intrauterine device or a double barrier method using condoms or a diaphragm plus spermicide) during the study and for at least one month after receiving the last dose of romidepsin. Male patients were to use a barrier method of contraception (condoms) during the treatment period and for at least 1 month thereafter. Hormonal methods of contraception such as the contraceptive pill or patch (particularly those containing ethinyl estradiol) were to be avoided due to a potential drug interaction.~* Use of topical steroids in the previous 2 weeks or systemic steroids in the previous 4 weeks.~* Having previously given consent to participate in this study.~* Concomitant use of CYP3A4 inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).